证券代码：300451 证券简称：创业慧康 公告编号：2025-047 二、股东本次减持前后持股情况 创业慧康科技股份有限公司 关于持股5%以上股东权益变动的提示性公告 持股5%以上股东飞利浦（中国）投资有限公司保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1.本次权益变动为持股 5%以上股东飞利浦（中国）投资有限公司（以下简 称"飞利浦"）实施股份减持计划，不触及要约收购。 2.本次权益变动后，股东飞利浦持有公司股份比例为 9.999996%，该股东在 公司的持股比例下降至 10%以下。 3.公司无控股股东及实际控制人，本次权益变动不会导致公司控股股东及 实际控制人发生变化，不会对公司治理结构及持续经营产生重大影响。 创业慧康科技股份有限公司（以下简称"公司"）于近日收到股东飞利浦 出具的《告知函》《简式权益变动报告书》，飞利浦已通过集中竞价方式减持 公司股份 560,500 股，占公司总股本 0.036182%（占剔除公司回购专用账户股份 后的总股本比例为 0.036292%）。本次权益变动后，股 ...

| 合 | 计 | | 560,500 | | 0.036292% | | --- | --- | --- | --- | --- | --- | | | | | 通过证券交易所的集中交易☑ | | | | 本次权益变动方式（可多选） | | | 通过证券交易所的大宗交易□ | | | | | 其他□ | | | | | | 3.本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 | | | | | | | 股东 | 股份性质 | | 本次变动前持有股份 | | 本次变动后持有股份 | | 名称 | | 股数(股) | 占总股本比 | 股数(股) | 占总股本比 | | | | | 例 | | 例 | | 飞利浦 | 合计持有股份 | 155,003,087 | 10.036288% | 154,442,587 154,442,587 | 9.999996% 9.999996% | | 其中：无限售条件 | | | | | | | 股份 | | 155,003,087 | 10.036288% | | | | 有限售条件股份 | | 0 0.000000% | 0.000000% | 0 | | | ...

Group 1 - The core point of the article is that a major shareholder of Chuangye Huikang plans to reduce their stake in the company by selling up to 9,294,748 shares, which represents 0.6018% of the total share capital [2] - The reduction plan will take place from July 31, 2025, to October 29, 2025, following a 15 trading day period after the announcement [2] - The shareholder has already completed the reduction, having sold 9,294,700 shares, which is exactly 0.6018% of the company's total shares [2]

1、股东减持股份情况 | 股东名称 | 减持方式 | 减持期间 | 减持均价（元/股） | 减持股数（股） | 减持比例 | | --- | --- | --- | --- | --- | --- | | 葛航 | 集中竞价 | 2025.7.31-2025.9.5 | 5.71 | 9,294,700 | 0.6018% | | | | 合计 | | 9,294,700 | 0.6018% | 2、股东本次减持前后持股情况 证券代码：300451 证券简称：创业慧康 公告编号：2025-045 创业慧康科技股份有限公司 关于持股5%以上股东减持计划实施完毕的公告 持股 5% 以上股东葛航先生保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 创业慧康科技股份有限公司（以下简称"公司"）于 2025 年 7 月 9 日披露 了《关于持股 5%以上股东减持股份预披露公告》（公告编号：2025-039），股 东葛航计划自上述公告发布之日起十五个交易日后的三个月内（2025 年 7 月 31 日至 2025 年 10 月 2 ...

证券日报网讯创业慧康9月8日在互动平台回答投资者提问时表示，公司将严格按照相关法律法规认真履 行信息披露义务，会关注相关股东减持情况，请以披露的公告为准，注意投资风险。 （文章来源：证券日报） ...

凭借这一产学研合作优势，创业慧康在2025年上半年共助力8家医院通过电子病历高等级评审（同比增 长14.3%，两家获六级），帮助医院提升安全、可控、规范、高效和智能水平。同时，助力24家单位通 过互联互通测评，其中一家获五级乙等。 近日，2025百度云智大会在北京国家会议中心二期盛大召开，其中以"大模型加速融入智慧医疗的跨越 式进化论"为主题的首届AI+医疗专题论坛于8月29日成功举办。创业慧康（300451）（300451.SZ）应邀 出席，公司副总裁、AI产品部负责人发表《大模型赋能医疗数据要素价值释放》主题演讲，作为核心 参与方加入百度智能云智慧医疗伙伴联盟。 创业慧康在医疗AI产品落地与HI-HIS项目交付上的扎实成果，正是其深耕医疗数字化领域的核心支 撑，也为此次参会的技术分享与生态合作奠定了坚实基础。 AI产品落地多场景，临床价值获数据验证 近年来，随着国产大语言模型的突破和相关政策发布，医疗AI进入产业化落地关键阶段，需求正经历 从"工具革新"向"体系重构"的质变。在此趋势下，创业慧康AI产品已覆盖临床医疗、患者服务、医院管 理等数十场景。其中，公司自主研发的BsoftGPT平台可接入第三方大模 ...

Group 1 - The core viewpoint of the news is the recognition of outstanding corporate secretaries in the capital market, highlighting the importance of their roles in corporate governance and investor relations [1][2] - The 11th Jin Qilin Golden Secretary Honor Roll was announced, with Hu Yan from Chuangyue Huikang receiving the Five-Year Achievement Award, showcasing her exceptional professional capabilities [1][2] - The Jin Qilin Golden Secretary selection process evaluates candidates based on information disclosure quality, investor communication effectiveness, and contributions to corporate governance and ESG initiatives [1] Group 2 - An excellent corporate secretary can effectively communicate company value in complex market environments and innovate communication methods while adhering to compliance [2] - Hu Yan's recognition reflects both her individual excellence in capital communication and the market's acknowledgment of Chuangyue Huikang's governance and value growth [2]

Core Viewpoint - The company reported a significant decline in revenue and a shift to net loss in the first half of 2025, primarily due to project delays and the early-stage delivery cycle of new products, particularly Hi-HIS [1][2]. Financial Performance - The company achieved a revenue of 577 million yuan in H1 2025, a year-on-year decrease of 20.65% [1]. - The net profit attributable to shareholders was -81 million yuan, compared to a profit of 27 million yuan in the same period last year [1]. - In Q2 2025, revenue was 286 million yuan, down 18.48% year-on-year, with a net profit of -65 million yuan, reversing from a profit of 15 million yuan in Q2 2024 [1]. Cost and Margin Analysis - The gross margin for H1 2025 was 51.45%, a decrease of 2.76 percentage points year-on-year [2]. - The sales, management, and R&D expense ratios were 7.47%, 18.96%, and 25.96%, respectively, with year-on-year changes of -1.06, +3.5, and +6.95 percentage points [2]. - R&D investment reached 215 million yuan, accounting for 37.32% of revenue, an increase of 14.62 percentage points year-on-year [2]. Product Development and Innovation - The company upgraded its product from HuiKang Cloud 1.0 to 3.0, transitioning from basic cloud services to an intelligent ecosystem [2]. - AI technology has been integrated into products, with significant results from the pilot launch of the AI Patient Tracking System (APTS) [2]. - The company is actively expanding its business boundaries in the fields of medical internet and smart health insurance, with a 3% year-on-year increase in new smart health insurance projects [2]. Strategic Partnerships and Collaborations - The company established a joint laboratory with Zhejiang University to develop AI medical products, focusing on the "启真" medical model and APTS, which has been implemented in dozens of hospitals [4]. - The collaboration aims to create a closed-loop system of production, learning, research, and application, covering various medical scenarios [4]. Future Outlook and Valuation - The company maintains its revenue forecast for 2025-2027 at 1.607 billion, 1.821 billion, and 2.071 billion yuan, respectively [5]. - A target price of 7.26 yuan is set, based on a 7.0 times price-to-sales ratio for 2025, reflecting the early-stage promotion of the Hi-HIS product [5].

Core Viewpoint - The stock price of Chuangye Huikang fell by 4% on August 27, closing at 5.52 yuan, indicating a decline in market performance and investor sentiment [1] Company Performance - Chuangye Huikang reported a revenue of 577 million yuan for the first half of 2025, representing a year-on-year decrease of 20.6% [1] - The company incurred a net loss attributable to shareholders of 80.55 million yuan, a significant decline of 394.3% compared to the previous year [1] - The company made provisions for credit and asset impairment totaling 93.32 million yuan, which negatively impacted the total profit for the period [1] Market Activity - On August 27, the net outflow of main funds was 56.38 million yuan, with a cumulative net outflow of 109 million yuan over the past five days [1] - The stock opened at 5.81 yuan, reached a high of 5.90 yuan, and a low of 5.52 yuan, with a trading volume of 944,700 hands and a transaction amount of 541 million yuan [1] Industry Focus - Chuangye Huikang operates in the software development sector, specifically focusing on healthcare information technology [1] - The company leverages cloud computing, big data, IoT, and artificial intelligence to drive product innovation and implement its "Huikang Cloud Strategy," providing comprehensive intelligent solutions [1]

Summary of the Conference Call for Chuangyue Huikang Company Overview - Chuangyue Huikang operates primarily in the healthcare industry, with 94% of its revenue derived from this sector, amounting to 5.42 billion yuan [2][4]. Key Financial Performance - The company reported a revenue of 5.76 billion yuan for the first half of 2025, a year-on-year decrease of approximately 20% [4]. - The net profit attributable to the listed company was negative 80.55 million yuan, significantly down from the previous year [4]. - Operating cash flow improved by 7.58% [2][4]. - R&D expenditure reached 215 million yuan, indicating strong investment in business growth and innovation [2][4]. Business Developments - The company secured 18 orders exceeding 10 million yuan each and added 18 software copyrights [2][4]. - Significant project advancements include the launch of the Hi Face project at six campuses of Suzhou Municipal Hospital and winning the bid for the Akesu grassroots medical project [2][4]. - The company assisted multiple medical institutions in achieving high-level electronic medical record (EMR) evaluations, with two institutions attaining Level 6 certification [4]. - The delivery of 36 Happy projects was completed, marking a 200% year-on-year increase [2][5]. Technological Innovations - Chuangyue Huikang launched the Huikang Cloud Book Intelligent System and collaborated with Zhejiang University to develop an AI patient tracking system, successfully recalling over 800 patients and improving early diagnosis rates by 42% [2][5]. - The IoT division has obtained 28 software copyrights and 9 patents [5]. Industry Insights and Policy Impact - The national "44,128" digital health plan provides clear direction for industry development, promoting new opportunities for companies with strong R&D capabilities [2][6]. - The company anticipates that the industry will gradually adapt to new policies over the next six months to a year, leading to significant business opportunities [6]. - The strict budget management of public hospitals and government departments affects the order fulfillment rhythm, resulting in challenges in accounts receivable collection and profit performance [7][8]. Challenges and Future Outlook - The company faces pressure on gross margins due to the coexistence of new and old products, which has increased costs [4][14]. - Asset impairment provisions increased by approximately 20 million yuan compared to the previous year, negatively impacting profits [3][8]. - Despite current challenges, the company remains optimistic about future demand release in the second half of 2025 and into 2026, driven by policy support [8]. AI and Healthcare Integration - There is a strong demand for AI technology in healthcare, with hospitals and government institutions seeking diverse applications [10]. - The company is focusing on integrated services from pre-hospital to post-hospital care, expanding functionalities to meet emerging needs [12]. Electronic Medical Records (EMR) Policy Outlook - The standards for EMR evaluations are becoming stricter, with a growing demand for high-level assessments [13]. - The establishment of regional data platforms and business exchange systems is expected to drive demand for EMR and related systems in the coming years [13]. Conclusion - Chuangyue Huikang is navigating a challenging environment with a focus on innovation and adaptation to policy changes, positioning itself for future growth in the healthcare sector.